Role of interleukin‑32 in cancer biology (Review) | Zendy

Haimeng Yan | Zendy; Donghua He | Zendy; Xi Huang | Zendy; Enfan Zhang | Zendy; Qingxiao Chen | Zendy; Ruyi Xu | Zendy; Xinling Liu | Zendy; Fuming Zi | Zendy; Zhen Cai | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Role of interleukin‑32 in cancer biology (Review)

Author(s) -

Haimeng Yan,

Donghua He,

Xi Huang,

Enfan Zhang,

Qingxiao Chen,

Ruyi Xu,

Xinling Liu,

Fuming Zi,

Zhen Cai

Publication year - 2018

Publication title -

oncology letters

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 0.766

H-Index - 54

eISSN - 1792-1082

pISSN - 1792-1074

DOI - 10.3892/ol.2018.8649

Subject(s) - cancer , biology , oncogene , proinflammatory cytokine , interleukin , cancer research , tumor microenvironment , molecular medicine , cytokine , cancer cell , cell cycle , immunology , cancer immunology , inflammation , immunotherapy , genetics

Interleukin-32 (IL-32), a novel proinflammatory cytokine, is highly expressed in various cancer tissues and in established cancer cell lines. IL-32 has been revealed to serve a crucial role in human cancer development, including tumour initiation, proliferation and maintenance. The expression of IL-32 is regulated by numerous factors, including genetic variations, hypoxia and acidosis in the tumour microenvironment. Understanding the underlying mechanisms of IL-32 expression and its function are critical for the discovery of novel therapeutic strategies that target IL-32. This is a review of the current literature on the regulation and function of IL-32 in cancer progression, focusing on the molecular pathways linking IL-32 and tumour development.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research